Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug;44(8):1894-1897.
doi: 10.2337/dc21-0300. Epub 2021 Jun 28.

Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial

Frederik Persson  1 , Peter Rossing  2   3 , Priya Vart  4 , Glenn M Chertow  5 , Fan Fan Hou  6 , Niels Jongs  4 , John J V McMurray  7 , Ricardo Correa-Rotter  8 , Harpreet S Bajaj  9 , Bergur V Stefansson  10 , Robert D Toto  11 , Anna Maria Langkilde  10 , David C Wheeler  12   13 , Hiddo J L Heerspink; DAPA-CKD Trial Committees and Investigators
Affiliations

Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial

Frederik Persson et al. Diabetes Care. 2021 Aug.

Abstract

Objective: The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) study demonstrated risk reduction for kidney and cardiovascular outcomes with dapagliflozin versus placebo in participants with chronic kidney disease (CKD) with and without diabetes. We compared outcomes according to baseline glycemic status.

Research design and methods: We enrolled participants with CKD, estimated glomerular filtration rate (eGFR) 25-75 mL/min/1.73 m2, and urinary albumin-to-creatinine ratio 200-5,000 mg/g. The primary composite end point was sustained eGFR decline ≥50%, end-stage kidney disease, or kidney or cardiovascular death.

Results: Of 4,304 participants, 738 had normoglycemia, 660 had prediabetes, and 2,906 had type 2 diabetes. The effect of dapagliflozin on the primary outcome was consistent (P for interaction = 0.19) in normoglycemia (hazard ratio [HR] 0.62 [95% CI 0.39, 1.01]), prediabetes (HR 0.37 [0.21, 0.66]), and type 2 diabetes (HR 0.64 [0.52, 0.79]). We found no evidence for effect modification on any outcome. Adverse events were similar, with no major hypoglycemia or ketoacidosis in participants with normoglycemia or prediabetes.

Conclusions: Dapagliflozin safely reduced kidney and cardiovascular events independent of baseline glycemic status.

Trial registration: ClinicalTrials.gov NCT03036150.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A: Forest plot of the primary composite outcome of ≥50% eGFR decline, end-stage kidney disease (ESKD), or death from cardiovascular (CV) or kidney causes with dapagliflozin compared with placebo by glycemic status at baseline. B: The treatment effect of dapagliflozin compared with placebo as a function of baseline HbA1c (continuous) for the primary outcome. The solid black line represents the HR of the treatment effect. The gray shaded area represents the 95% CI around the treatment effects. The dotted horizontal line represents a HR of 1 (i.e., no difference between randomized groups).
See this image and copyright information in PMC

References

    1. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. .; DAPA-CKD Trial Committees and Investigators . Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020;383:1436–1446 - PubMed
    1. Cannon CP, Perkovic V, Agarwal R, et al. . Evaluating the effects of canagliflozin on cardiovascular and renal events in patients with type 2 diabetes mellitus and chronic kidney disease according to baseline HbA1c, Including those with HbA1c <7%: results from the CREDENCE Trial. Circulation 2020;141:407–410 - PubMed
    1. McMurray JJV, Solomon SD, Inzucchi SE, et al. .; DAPA-HF Trial Committees and Investigators . Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:1995–2008 - PubMed
    1. Anker SD, Butler J, Filippatos G, et al. . Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-Reduced Trial. Circulation 2021;143:337–349 - PMC - PubMed
    1. Færch K, Blond MB, Bruhn L, et al. . The effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the PRE-D Trial): a multi-arm, randomised, controlled trial. Diabetologia 2021;64:42–55 - PubMed

Publication types

MeSH terms